RuiPai Medical Secures Hundreds of Millions in Series B Funding to Build a Global Leading Disposable Endoscopy Platform

VCBeat has learned that Guangzhou Ruipai Medical Devices Co., Ltd. (“REDPINE”) recently announced the completion of its Series B financing, raising hundreds of millions of yuan. The round was led by a renowned investment institution, with participation from Guofang Capital and Xiangtang Capital, among others. Existing shareholders STIC Capital, Oriza Holdings, and Shenzhen CO-WIN Venture CAPITAL Investmen Limited continued their support. Dianshi Capital served as the exclusive financial advisor. The funds raised will be used to further expand the R&D pipeline, increase production capacity, conduct clinical trials, and promote and educate the market on existing products.

REDPINE, established in 2015 and headquartered at Guangzhou International Bio Island, is a national high-tech enterprise. Committed to becoming a leading integrated R&D and manufacturing platform for disposable electronic endoscopes in China, REDPINE provides cost-effective, comprehensive minimally invasive surgical solutions, including disposable endoscopes, to the global market.

Leveraging the founding team’s deep understanding of clinical pain points and the endoscopy industry, REDPINE has developed a portfolio of more than ten products, covering numerous departments including urology, gynecology, respiratory medicine, general surgery, and gastroenterology. Unlike most companies that focus on single-product offerings such as disposable flexible ureteroscopes or disposable bronchoscopes, REDPINE’s R&D strategy for disposable endoscopes encompasses both traditional flexible and rigid endoscopes, as well as major and minor endoscope categories. Additionally, its portfolio extends to disposable therapeutic devices used under endoscopic guidance.

Disposable Electronic Cystoscope

Disposable Electronic Ureteropyeloscope Catheter

In the context of achieving common prosperity, single-use endoscopes reduce procurement and operational maintenance costs for hospitals, enabling more primary-care institutions to perform minimally invasive procedures and effectively lowering the medical expenses patients incur when seeking care far from home. Furthermore, as single-use endoscopes eliminate the need for sterilization, they facilitate back-to-back surgeries, shorten waiting times for out-of-town patients at tertiary hospitals, and alleviate the financial burden on patients to some extent. In the future, REDPINE will continue to implement various cost-reduction measures to drive down the end-user price of single-use endoscopes and expand insurance coverage, thereby benefiting a broader patient population.

To date, REDPINE has filed more than 50 patents of various types, with over 30 granted, breaking the technological monopoly held by international medical device giants in this field. REDPINE has launched its overseas commercialization efforts, initiating exports to CE-certified regions and pursuing FDA registration, earning widespread acclaim from foreign distributors and physicians.

While completing the development of existing products, the company has established a modular design philosophy by modularizing core components; deployed high-definition host platforms and independently developed image processing algorithms; and introduced automated equipment to rapidly build large-scale production capacity. These initiatives have laid a solid foundation for the company to develop a wide range of products in a short period and further advance toward becoming an internationally leading platform enterprise specializing in disposable endoscopes.

Mr. Yi Feng, Co-founder and Chairman of REDPINE, previously served as a frontline clinical physician at Hunan Children's Hospital. After leaving clinical practice, Mr. Yi joined leading medical device companies, including Guangzhou Vitae, Hitachi Medical Systems, and Olympus, where he was engaged in the frontline promotion of endoscopic technologies. Subsequently, Mr. Yi led his team to establish REDPINE, shaping its management team into one of the few in China that combines deep insights into clinical endoscopy needs, exceptional commercialization capabilities, and R&D and production management experience from frontline multinational enterprises.

Commenting on the successful completion of this funding round, Yi Feng stated, “We extend our gratitude to both new and existing shareholders for their recognition and support of REDPINE. Over the past year, REDPINE has achieved a significant leap in the manufacturing of single-use endoscopes, progressing from small-batch production to mass production, and ultimately to automated large-scale manufacturing. We have broken through core underlying technologies and established substantial technical reserves. Moving forward, supported by technological advancements and medical insurance policies, we will enhance the accessibility of top-tier medical devices and fulfill REDPINE’s social responsibility. Meanwhile, we will continue to advance R&D efforts, expanding the application of single-use endoscopes across more clinical departments and surgical procedures. Targeting the domestic endoscopic diagnosis and treatment market, which sees nearly 70 million cases annually, as well as the broader overseas markets, we aim to make minimally invasive medical technologies accessible to more patients.”